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Abstract: Effective and resource-efficient long-term management of multimorbidity is one of 
the greatest health-related challenges facing patients, health professionals, and society more 
broadly. The purpose of this review was to provide a synthesis of literature examining multi-
morbidity and resource utilization, including implications for cost-effectiveness estimates and 
resource allocation decision making. In summary, previous literature has reported substantially 
greater, near exponential, increases in health care costs and resource utilization when additional 
chronic comorbid conditions are present. Increased health care costs have been linked to elevated 
rates of primary care and specialist physician occasions of service, medication use, emergency 
department presentations, and hospital admissions (both frequency of admissions and bed days 
occupied). There is currently a paucity of cost-effectiveness information for chronic disease 
interventions originating from patient samples with multimorbidity. The scarcity of robust 
economic evaluations in the field represents a considerable challenge for resource allocation 
decision making intended to reduce the burden of multimorbidity in resource-constrained health 
care systems. Nonetheless, the few cost-effectiveness studies that are available provide valuable 
insight into the potential positive and cost-effective impact that interventions may have among 
patients with multiple comorbidities. These studies also highlight some of the pragmatic and 
methodological challenges underlying the conduct of economic evaluations among people who 
may have advanced age, frailty, and disadvantageous socioeconomic circumstances, and where 
long-term follow-up may be required to directly observe sustained and measurable health and 
quality of life benefits. Research in the field has indicated that the impact of multimorbidity 
on health care costs and resources will likely differ across health systems, regions, disease 
combinations, and person-specific factors (including social disadvantage and age), which rep-
resent important considerations for health service planning. Important priorities for research 
include economic evaluations of interventions, services, or health system approaches that can 
remediate the burden of multimorbidity in safe and cost-effective ways.
Keywords: chronic disease, comorbidity, economic, complexity, cost-effectiveness, burden
Background
Effective and efficient long-term management of multiple comorbid chronic diseases 
is one of the greatest health-related challenges facing patients, health professionals, 
and society more broadly who fund health care services.1–6 Multimorbidity poses 
substantial difficulties for health care policy and resource allocation decision making 
in the presence of imperfect information, aging populations, and increasingly undesir-
able societal lifestyle characteristics.7–10 The complexity associated with management 
of multimorbidity has a variety of sources. Not the least of these are inconsistencies 
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across research literature in the field beginning at the very 
foundation of the conceptualization and definition of mul-
timorbidity, but extending throughout observational and 
interventional studies seeking to describe epidemiological 
characteristics and investigate potential solutions to alleviate 
the burden associated with multimorbidity.9,11 For the most 
part, multimorbidity has been defined loosely as the presence 
of multiple chronic conditions, albeit that no gold standard 
definition presently exists.9,11 Differences have been reported 
in terms of the number or types of conditions required to be 
present before a classification of multimorbidity is applied, 
or in the quantification of the extent of multimorbidity pres-
ent.11–15 As a result, multimorbidity has been measured in a 
variety of ways.11
Approaches to quantifying multimorbidity in studies 
considering costs and health care resource usage have tended 
to focus on diagnosis-based indices.1,9,16–19 These indices typi-
cally include counts of diagnoses with or without a weighting 
system dependent on the specific index used.1,9,15–19 Perhaps 
the most well-known of these is the Charlson Comorbidi-
ties Index and its adaptations.20,21 Other approaches include 
indices derived from medication data, as well as groups of 
medications or diagnoses groups.15,18 For example, the modi-
fied Chronic Disease Score uses medications and includes 28 
disease categories weighted from prior regression models.22
There have been several key conclusions from literature 
examining the definition and measurement of multimorbidity 
that have relevance for understanding health care costs and 
resource utilization.11,13,15,23 First, there are inconsistencies 
in the number and types of diagnoses used to define multi-
morbidity across measurement approaches.9,11,13,23 This is a 
source of difficulty when comparing resource utilization and 
health care cost information across studies. Second, there 
are nuances between the conceptualization of cormorbidity 
or multimorbidity, in comparison to morbidity burden that 
includes other health-related factors, or patient complexity 
that includes non health-related patient-level factors.23 For 
a detailed discussion of the conceptualization of constructs 
related to multimorbidity, see the review by Valderas et al.23 
Third, the number of conditions attributed to research par-
ticipants is likely to be dependent on the data sources and 
potentially the incentives that may influence whether a com-
prehensive list of health conditions has been documented.9 
For example, the incentives for a busy clinician in a primary 
care general practice setting may substantially differ from 
the incentives of a data coder in an insurance-claim setting.
Consideration of incentives for data coding is just one of 
a broader spectrum of data-related issues that are worthy of 
consideration for health systems internationally as they look 
to identify opportunities to improve the effectiveness and 
efficiency of services for people with multimorbidity. This 
is an area of importance as the use of “big data” analytical 
approaches to better understand, plan for, and optimize health 
care resource allocation become an increasingly mainstream 
activity for health systems internationally. Some other chal-
lenges worthy of consideration to improve the richness of 
routinely recorded information in increasingly digitalized 
health systems may include enhanced compatibility of digital 
systems across hospital and community health care interfaces 
and standardization of approaches to disease classifications 
that also include potential for quantification of disease sever-
ity (rather than simply the presence or absence of a condition) 
among people with multimorbidity. Despite differences in 
the definition and measurement of multimorbidity, there is 
consensus that multimorbidity is a growing concern for health 
care policy makers trying to provide optimal health care 
services within resource-constrained environments.6,12,14,24–29
Three important and interrelated challenges for con-
temporary health care policy include the aging nature of 
population demographics, development of chronic diseases 
at younger ages, and socioeconomic inequalities in the dis-
tribution of multimorbidity and its effects.6,14,25,29,30 Older age, 
undesirable lifestyle factors, and socioeconomic deprivation 
have been consistently reported to be associated with the 
development of chronic disease, and in particular, multiple 
chronic diseases.5,10,14,19,29–32 While living to older ages ought 
to be celebrated, the increasing proportion of older adults in 
the population, and increasing proportion of younger adults 
with multimorbidity who will live to advanced ages, has 
health care policy implications, particularly for the funding 
of sustainable health care services.6,33–35
The demand placed on health services by increasing 
numbers of older adults with chronic diseases is compounded 
by earlier onset of chronic disease that is accompanying 
increasingly sedentary lifestyles and undesirable dietary 
behaviors.5,10,36–39 This earlier onset of chronic disease does 
not affect all segments of society equally, with the onset of 
multimorbidity having been estimated to occur 10–15 years 
earlier among people living in areas classified as being the 
most socioeconomically deprived in comparison to the least 
deprived.29
There has been substantial investment in public health 
initiatives and health care system redesign in some coun-
tries attempting to reduce the impact of multimorbidity and 
patient complexity on individuals and societies, particularly 
in areas where socioeconomic deprivation is prevalent.30,40–42 
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For example, in the United Kingdom, health care reforms last 
decade introduced a pay for performance initiative called the 
quality and outcomes framework.30,40 This initiative provided 
primary care practices with financial incentives for undertak-
ing specified activities related to the management of chronic 
disease, including secondary prevention. Some measureable 
improvements in outcomes for people with multimorbidity 
and complex health states including older adults and people 
from socioeconomically deprived areas have been observed, 
albeit that improvements have been modest and below initial 
targets.30,40 Nonetheless, there is undoubtedly further oppor-
tunity to improve the capacity of health systems to effectively 
and efficiently reduce the burden of multimorbidity on indi-
viduals and societies.
There has been an increase in research interest regard-
ing how to best manage chronic disease, and perhaps more 
recently, a rapid increase in studies investigating multimor-
bidity. The increasing interest in chronic disease comorbidity 
and multimorbidity can be demonstrated with a search of the 
PubMed database for the full calendar years from 1985 to 
2014 using the search string:
((multimorbid*) or (multiple comorbid*) or (multiple 
chronic condition*) or (multiple chronic disease*)).
This search yielded 3,054 hits. The number of hits per 
calendar year is displayed in Figure 1 (darkest shade). For the 
purpose of comparison, the total number of citations added 
to the PubMed (Medline) database over the same period 
is also displayed in Figure 1 (light shade). There has been 
steady growth in the total number of citations being added 
each year. However, there has been rapidly accelerating 
growth in multimorbidity publications since approximately 
2003. It is also noteworthy that approximately 1,000 of these 
citations were identified from the multiple comorbid* term; 
likely describing the level of comorbidity in a study sample, 
rather than multimorbidity being the focus of the investiga-
tion. Repeating this search string without the comorbid* term 
substantially reduced the number of hits to 1,871, although 
the same pattern of rapid recent growth in citations per year 
was observed (not displayed).
The purpose of the remainder of this review is to provide a 
synthesis of literature examining multimorbidity and resource 
utilization, as well as discuss implications of multimorbidity 
on intervention cost-effectiveness estimates and resource 
allocation decisions, as well as highlighting some priorities 
for future research in the field regarding health care resourc-
ing and costs.
Health care costs and resources 
utilization
Attributing costs and resource utilization to specific diseases 
can be complicated by the presence of multiple chronic 
 diseases. Various methodological approaches for inclusion 
of comorbidities in studies that investigate the cost of an 
illness have been examined.43–47 A key principle outlined in 
prior literature in this field is that diseases that occur in addi-
tion to a disease of interest may be classified in one of four 
ways (Figure 2).43 First, a disease of interest may be caused 
by another disease. Second, two diseases may be correlated 
with a causal link. Third, the disease of interest may cause 
another disease. Fourth, two diseases may have no causal link 
and have only weak or no significant association.43
These differences in the categorization of correlation 
and causal relationships have been demonstrated to have 
substantial effect on cost of illness estimates.43 In a study 
investigating the methods for determining the cost of ill-
nesses, Rizzo et al43 concluded that when determining the cost 
of a particular illness of interest when other chronic diseases 
may be present in a sample, those comorbidities falling in the 
second, third, and potentially first aforementioned categories 
(Figure 2) should be taken into account when modeling 
disease costs. Although this decision may not always be 
straightforward, their rationale was supported by analyses 
of Medical Expenditure Panel Survey data from a very large 
sample.43 In summary, failing to adjust for conditions that 
are correlated but have no causal relationship (Category 2) 
may lead to an overestimation of the cost of the illness of 
interest. On the other hand, failing to adjust for the cost of 
conditions caused by the condition of interest (Category 3) 
may lead to an underestimation of the cost of the illness of 
interest. However, the conceptual rationale for (Category 1) 
conditions that cause the condition of interest is less clear. It 
would seem that under some scenarios, no adjustments for the 
Figure 1 Number of citations per year for PubMed search for the multimorbidity 
search string (dark blue) in comparison to number of citations added (light blue).
900,000
600
500
400
300
M
ul
tim
or
bi
di
ty
 c
ita
tio
ns
A
ll 
P
ub
M
ed
 (
M
ed
lin
e)
 c
ita
tio
ns
200
100
0
771,429
642,857
514,286
Year
385,714
257,143
128,571
0
19
85
19
90
19
95
20
00
20
05
20
10
20
14
700
 
R
is
k 
M
an
ag
em
en
t a
nd
 H
ea
lth
ca
re
 P
ol
icy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
1.
18
1.
30
.1
02
 o
n 
08
-M
ar
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Risk Management and Healthcare Policy 2016:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
146
McPhail
Category 1 conditions could lead to overestimates of the cost 
of the illness of interest,48 while in other scenarios complete 
adjustment for the Category 1 condition would lead to an 
estimate of the cost of illness for cases that were not caused 
by Category 1 condition, which may also be problematic.43 
Therefore, the potential adjustment for conditions in a causal 
relationship with the condition of interest may need to be 
considered on a case-by-case basis in cost of illness estimates. 
Appropriate sensitivity analyses may also need to be prepared 
to examine the potential influence of analytical decisions on 
the cost of illness estimates when multimorbidity is likely to 
be present in the population.
Quantifying costs attributable to specific diseases or risk 
factors is challenging, but potentially useful for understand-
ing the relative burden of each chronic condition. Prior 
research has indicated that some specific combinations of 
diseases may be synergistic in terms of their impact on func-
tion and quality of life.49–51 Although literature in the field is 
still emerging, it is also likely that some specific combinations 
of chronic diseases may have a disproportionate impact on 
health care utilization than simple addition of the respective 
single disease burdens.43 However, there is already consensus 
that more chronic diseases present are typically associated 
with greater health care costs.1,9,16–19,43
A review conducted by Lehnert et al1 examined health 
care utilization among older adults with multiple chronic 
conditions in 35 studies. The principal finding was the 
 relationship between additional chronic conditions and 
health care costs was curve-linear, near exponential. While 
a large proportion of the included studies originated in 
the United States (n=23), the remainder of studies were 
 distributed across several regions internationally, adding 
some weight to the ability of these findings to be generalized.1
There is consensus that multimorbidity is associated 
with substantially higher health care costs, but important 
further considerations for healthcare policy are the patterns 
of health service utilization among people with multimorbid-
ity.1,15,19,52,53 The weight of evidence investigating the patterns 
of health resource utilization associated with multimorbidity 
has reported that multimorbidity is associated with higher 
levels of utilization across resource types including medica-
tions,31,53–57 primary care, and outpatient specialist occasions 
of service,13,14,17,53,58,59 as well as emergency department 
presentations and hospitalizations.19,60–62 However, there 
is considerable variation in the magnitude of increases in 
resource utilization reported between studies, health systems, 
and data sources from which study findings were derived.
Studies investigating primary and other ambulatory care 
have indicated that the occasions of accessing physician 
services have been consistently higher among people with 
multiple chronic diseases, even after adjustment for poten-
tial confounders like age, sex, and income.13,14,17,53,58,59,63 For 
example, a Canadian study by Rapoport et al63 reported 51% 
greater use of physician services for each additional chronic 
disease. It is also noteworthy that people with multimorbidity 
seem more likely to see a specialist physician for a chronic 
condition that would usually fall within the scope of a primary 
care service.59 In summary, older adults with multimorbid-
ity have been reported to utilize between two and five times 
more physician appointments than their peers without chronic 
conditions.64–66
Multiple chronic diseases have also been associated 
with greater medication usage. Estimates of the amount of 
additional prescription medications per additional comor-
bidity have varied widely depending on data sources and 
study context.31,53–57 Fahlman et al54 investigated prescription 
medication usage in the last year of life among Medicare ben-
eficiaries in the United States. They reported that people with 
five or more comorbidities used an additional eight prescrip-
tions for each additional comorbidity during their last year of 
Figure 2 A comorbid condition may 1) cause, 2) be correlated without causality, 3) be caused by, or 4) have no causal relationship and no (or weak) correlation with a 
condition of interest in cost of illness studies.
Disease of interest
3) Comorbidity
caused by disease
of interest
2) Correlated
(noncausal)
4) Not or weakly
correlated
(noncausal)
1) Comorbidity
caused disease of
interest
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life.54 Moxey et al55 investigated costs of medications among 
the elderly. They concluded that the category of patients with 
three or more comorbidities utilized prescription medications 
incurring an average cost 6.6 times greater than peers without 
comorbidities, and 2.1 times greater than peers with one or 
two comorbidities.55 Similar patterns of medication usage 
among non-elderly adults with and without multiple chronic 
conditions have also been reported.31,53
Multimorbidity has also been associated with emergency 
department presentations and hospital admissions.19,60–62,64 A 
study by Schneider et al64 among older adults in the United 
States reported that patients with three or more chronic 
conditions utilized 25 times more hospital bed-days during 
14.6 times more hospital admissions than peers without any 
chronic conditions. This pattern of positive associations 
between multimorbidity and hospital resource utilization 
has been consistently reported across a range of other studies 
in the field.19,60–62 The association between multimorbidity 
and hospital admissions is also consistent with observations 
of greater numbers of emergency department presenta-
tions, as well readmissions to hospital following discharge, 
among people who have greater numbers of chronic health 
conditions.19,61,67
The impact of multimorbidity on costs and resource 
utilization extends beyond insurers and government funding 
of health care systems to individual patients who directly 
experience out-of-pocket costs associated with their health 
care usage.45,66,68–70 For example, the out-of-pocket costs are 
reported as being 2.1 times higher for older adults with mul-
tiple chronic conditions than those without multiple chronic 
conditions.57 It is also noteworthy that out-of-pocket costs 
for people with multimorbidity are increasing at a rate faster 
than wage growth or broader consumer inflation levels and 
with great potential to adversely affect the lives of the most 
vulnerable members of society, particularly those without 
adequate health insurance coverage or access to universal 
health care systems.14,36,37,66,71
Multimorbidity underrepresented in 
trial-based economic evaluations
Trial-based economic evaluations are an invaluable approach 
for understanding the cost-effectiveness of health inter-
ventions. However, cost-effectiveness estimates of health 
interventions derived from randomized controlled trials may 
often only include highly selected patient samples. Inclusion 
and exclusion criteria for clinical trials of physical or mental 
health interventions may result in underrepresentation of 
complex patients, including patients with multiple chronic 
conditions.72–75 This selectivity permits rigorous evalua-
tion of the effect of an intervention on a specific condition, 
under tightly regulated circumstances and sample charac-
teristics, relative to a control or comparator intervention 
under  comparable circumstances and sample characteristics. 
 Conducting economic evaluations derived from clinical trials 
is worthwhile. However, it is noteworthy that cost-effective-
ness estimates derived from patients without multiple chronic 
conditions receiving a clinical trial intervention may not be 
generalizable to patients with multiple chronic conditions 
who receive the same intervention.76–78
The lack of cost-effectiveness information available for 
chronic disease interventions derived from people with mul-
timorbidity is concerning.14 A Cochrane systematic review 
published in April 2012 that examined the effect of primary 
care and interventions in community settings for people 
with multiple chronic conditions identified ten trials for 
inclusion; however, there were no accompanying economic 
evaluations.14 The authors of the review postulated that cost 
savings were plausible based on some favorable interven-
tion effects related to pharmaceutical use and reductions 
in chronic disease risk factors, but the cost-effectiveness 
of interventions were not specifically reported. Studies in 
the field since the aforementioned Cochrane review have 
also rarely considered cost-effectiveness estimates.79,80 The 
paucity of cost-effectiveness data to inform allocation deci-
sions in the field of multimorbidity remains a concern.14 To 
highlight the relative scarcity of cost-effectiveness studies in 
the field of interventions for people with multimorbidity, the 
following search string was entered into PubMed for January 
1, 1985 to September 26, 2015:
((multimorbid*) or (multiple comorbid*) or (multiple 
chronic condition*) or (multiple chronic disease*)) and 
((economic evaluation*) or (cost-effect*))
In summary, the search yielded only 50 citations, of 
which two articles were describing protocols for studies 
that have commenced and are intending to include eco-
nomic evaluations,12,81 and four were reports of completed 
cost-effectiveness studies with a focus on patients with 
 multimorbidity.67,82–84 The remainder were not reporting 
new cost-effectiveness data for chronic disease interven-
tions among people with multimorbidity. This search was 
not intended to identify all cost-effectiveness studies that 
may have included patients with more than one chronic 
condition. Instead, its purpose was to highlight the paucity 
of cost-effectiveness research in the field in contrast to the 
increasing number of studies examining multimorbidity that 
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have been reported and identified using the same search string 
without the addition the cost-effectiveness terms (Figure 1).
Cost-effectiveness of 
multimorbidity interventions
Despite the relative scarcity of cost-effectiveness studies 
among interventions targeted at people with multimorbidity, 
there are several cost-effectiveness studies of multimorbidity 
that provide valuable insight into the potential impact that 
interventions may have among patients with comorbidity, 
as well as some of the challenges underlying the conduct 
of economic evaluations in the field. A study by Ritzwoller 
et al83 investigated a 2-year moderate intensity weight-loss 
intervention delivered to inner-city, high-risk patients with 
both hypertension and obesity (and other comorbidities) 
from racial or ethnic minorities (predominantly Black/Afri-
can American, and Hispanic) as part of a randomized trial. 
The authors concluded that the additional intervention cost 
per kilogram of weight loss or per mmHg improvement in 
blood pressure was higher than the amount that Medicare 
and Medicaid reimburse physicians for obesity counseling, 
and higher than products otherwise commercially available.83 
However, future health benefits and health care costs saved 
among a high-risk clinical population such as this are likely to 
be important considerations regarding the cost-effectiveness 
of the program, but were not within the scope of the assess-
ments and analyses.
Long-term or lifetime modeling of potential attainment 
of health benefits (and costs) may be required to demon-
strate tangible health benefits and large reductions in health 
service utilization for some multimorbidity interventions.85,86 
Unfortunately, long-term modeling may also come with 
untenable levels of uncertainty that preclude meaningful 
conclusions being drawn.85,86 In particular, it may be difficult 
to determine how long intervention effects from lifestyle 
behavior change interventions will last.
Katon et al87 reported a randomized trial that investigated 
a collaborative care intervention delivered by physician 
supervised nurses and primary care physicians targeted at 
improving depression and physiological parameters among 
patients with depressive disorders with either diabetes or 
coronary heart disease. The authors concluded favorable 
findings regarding the cost per quality-adjusted life years 
(QALYs) gained from the intervention within the study 
follow-up period.88 However, it is noteworthy that QALYs 
were not directly measured in this study. Instead, QALYs were 
estimated using a regression model derived from a prior 
cohort study among patients with diabetes.88,89
This two-step approach of modeling QALYs on the basis 
of prior research offers pragmatic advantages in terms of 
being able to estimate QALYs from changes in physiologi-
cal parameters.88 However, the prior model from which the 
QALY estimates were generated was taken from a sample of 
people with diabetes, but not necessarily comorbid depres-
sion or coronary heart disease.89 The impact of estimating 
QALYs in this way, versus direct measurement from patient 
self-reports, in their study is uncertain in terms of the accu-
racy and precision of QALY estimates. This is not a criticism 
of the investigators, who ought to be commended for their 
contributions to the field and their transparent analysis and 
reporting, but rather this demonstrates something of the chal-
lenges that exist in producing robust economic evaluations 
to inform policy and practice.
There are also more general pragmatic challenges regard-
ing the quantification of costs and effects among people with 
multiple chronic conditions. The aforementioned study by 
Katon et al88 included a 2-year follow-up and demonstrated 
benefits in physiological parameters that were modeled to 
estimate QALY gains.89 In practice, interventions for some 
combinations of chronic diseases may require many years of 
ongoing intervention (and follow-up) among large samples 
before benefits can be directly observed.90–92 For example, a 
reduction in the rate of stroke or myocardial infarction may 
not be directly observable within the scope of most research 
investigations. The probabilistic modeling of future health 
benefits and economic costs may provide insight into the 
likelihood of whether interventions may be considered cost-
effective over longer time horizons in the absence of extensive 
longitudinal observation.85,86,93 However, in the context of 
finite intervention and observation periods being used as 
a foundation for probability estimates among multimorbid 
patients, the duration of intervention effect on risk reduction 
for inclusion in cost-effectiveness models may have levels of 
uncertainty that are difficult to quantify.
On the other hand, some interventions for people with 
multimorbidity may have immediate impacts on health-
related quality of life that are of sufficient magnitude to 
justify allocation of resources.82,88 However, it is noteworthy 
that calculating QALYs attributable to an intervention may 
be complicated among people with multiple health conditions 
due to both pragmatic considerations as well as habituation 
effects or “response shift”.94,95 In this context, response shift 
refers to internal changes in the way that individuals con-
ceptualize, prioritize, and value their own health states when 
reporting their health-related quality of life over longitudinal 
assessment points. This may occur as part of an adaptive or 
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 self-preserving process that enables people in poor health 
states with multimorbidity to reconsider how they concep-
tualize and value their own health state.
There has been a great deal written about people’s potential 
to adapt to poor health-related circumstances over time and 
potentially maintain positive self-perceptions of their own 
quality of life.96–98 This may generally be considered a favor-
able adaptation for the individual, but these adaptations have 
the potential to invalidate QALYs derived from longitudinal 
health-related quality of life assessments if respondents have 
systematically altered the way they conceptualize, prioritize, 
and value aspects of their own health-related quality of life 
between assessments.94,95,99–101 If these adaptations occur in a 
systematic way in a group of study participants, this may lead 
to response shift trend that under or overestimates QALYs 
attributable to an intervention, or potentially even the direc-
tion of effect.95,101,102 Although methods to adjust for these 
adaptations have been proposed, the impact of these adapta-
tions (and methods of adjustment) on QALY estimates among 
people with multimorbidity derived for the purpose of guiding 
resource allocation decisions is currently unknown.102–105
Other pragmatic challenges may include difficulty with 
the completion of self-reported health-related quality of life 
instruments by people who may have low levels of health 
literacy, potential cognitive impairments, poor vision, and 
other deficits associated with age-related frailty or poor 
health states.106–109 Proxy reporting of health-related quality 
of life for the purpose of QALY estimates may be justified in 
some cases. However, proxy reporting is also accompanied 
by its own set of challenges including determining who the 
most appropriate proxy is and the perspective from which 
the proxy should report.110–112
Challenges in resources allocation 
decision making
The relative scarcity of robust economic evaluations quantify-
ing the cost-effectiveness of interventions for multimorbidity 
creates challenges for resource allocation decision making. 
Nonetheless, this does not negate the need for judicious 
allocation of resources to attempt to stem the burden of 
multimorbidity internationally, albeit in the presence of 
imperfect information. Perhaps one of the clear messages 
arising from both health and economic data pertaining to 
multimorbidity is that the best course of action may be to 
prevent the development of multiple chronic diseases at the 
outset.1,14,25,38,113,114
It has been proposed that poorly targeted primary preven-
tion activities typically increase costs, whereas appropriately 
targeted primary (or secondary) prevention activities are more 
likely to be cost-effective.115 While this is likely to be true 
in many cases, exceptions may include brief and relatively 
inexpensive interventions (like low-cost vaccines) that may 
be cost-effective in preventing severe long-lasting conditions, 
particularly when there is potential for population coverage 
that can all but eliminate the presence of a condition within 
an entire population and yield long-term benefits. Perhaps 
there is no better case in point than polio vaccination that, 
from a cost-effectiveness point of view, may be considered a 
dominant strategy (in that it is both effective and cost saving 
from society’s perspective).116 However, this is in contrast 
to most primary prevention activities that have potential to 
prevent chronic disease but carry a net financial cost, which 
may or may not exceed willingness to pay thresholds for 
agencies that fund primary prevention activities.116,117
The curve-linear, near-exponential cost of health care 
associated with additional chronic diseases1 may indicate 
that cost-effective appropriately targeted secondary preven-
tion interventions should be considered an important line 
of defense for reducing the burden of multimorbidity in a 
cost-efficient way.118–121 This may be a somewhat idealist 
notion in the midst of current secular demographic trends. 
Nonetheless, it is plausible that secondary prevention may 
have some efficiency gains (perhaps in comparison to primary 
prevention) when it can be targeted to priority clinical groups 
at very high risk of subsequent negative health events and 
disease combinations.71,79,118–120,122 This may result in greater 
resource utilization avoidance per effective preventative 
intervention delivered in comparison to broader primary 
prevention interventions that may have larger number needed 
to treat or number needed to screen values.123–127
It is also noteworthy that the intervention studies and 
economic data that have been reported to date indicate that 
interventions for multimorbidity have the potential to be 
effective and cost-efficient,67,84 even in the absence of robust 
economic evaluations. For example, studies investigating 
various potential integrated care models targeting specific risk 
factors among patients with multimorbidity have generally 
reported positive findings.14,79,84 The additional per-patient 
labor costs, potentially from nursing or allied health profes-
sionals, for appropriately coordinated care for patients with 
multimorbidity may not be particularly expensive in com-
parison to usual care approaches that are less integrated and 
less effective.14,67,79,84 Similarly, interventions that promote 
chronic disease self-management and beneficial lifestyle 
changes have also not been associated with particularly large 
per-person intervention costs, even when costs of supports 
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provided using contemporary communication technologies 
that may enhance the longevity of behavior change interven-
tions are taken into account.2,67,114,128
An important risk when considering the potential alloca-
tion of resources for society is the risk of cost-shifting versus 
true efficiency gains in the context of care for people with 
multimorbidity. Effective models of primary and community 
care that reduce demand on hospital and specialty services 
have great potential to generate a net reduction in health care 
resource utilization, particularly due to high costs associated 
with hospital admissions.8,53,62 An approach that leads to a 
net reduction in health care resource usage is likely to be 
embraced in health systems where there is a single health 
care funder perspective that drives resource allocation deci-
sions; this may include nationalized health services. However, 
approaches that lead to a net reduction in health care resource 
utilization may not always be considered favorable for each 
individual segment of the health system when funding of the 
health system is fragmented, and incentives do not adequately 
reward judicious resource allocation decisions within each 
affected segment of the system.129–132
Although an intervention for multimorbidity may lead to 
a net reduction in costs, a whole-of-system approach may be 
required to make appropriate resource allocation decisions 
when intervention costs and resource savings affect  different 
segments of the health care system.130–133 The Australian 
health care system is an interesting case in point where the 
funding of health care is fragmented.134 In the Australian 
system, primary care and medications are largely funded by 
the Australian federal government through taxation (acting 
as national insurance scheme), whereas public hospitals are 
coordinated in local hospital and health services that receive 
funding via individual state governments (albeit with federal 
government contributions). One of the greatest benefits 
of high-quality primary care and community services for 
chronic diseases may be a reduction in hospital presentations 
or lengths of stay in hospital.14,79 However, in the presence 
of a fragmented funding model where benefits yielded in 
secondary or tertiary care require greater investment in of 
resources in primary care, a policy decision to allocate a 
higher proportion of a finite resource pool to primary health 
care would require consideration of health benefits to patients 
and the health care system more broadly.
There may be benefits for health care reforms and imple-
mentation of coordinated care strategies for people with 
multimorbidity and complex care needs among systems with 
less fragmentation, such as the United Kingdom’s National 
Health Service (and perhaps somewhat similar nationalized 
health services in the Netherlands and New Zealand). In 
these health systems, patients tend to register with general 
practices in community-based primary care settings that act 
as gateways and coordination points for referrals to more 
specialized care.135 Although this approach is not unique to 
nationalized health services, a single health care funding 
agent (eg, a federal government) may solidify an incentive 
for efficient coordinated care using this approach without any 
incentive for adverse cost-shifting to segments of the system 
that are funded by another funding agent (eg, provincial or 
state governments, private health insurers, or out-of-pocket 
cost’s for patient). In this regard, a survey of the coordination 
of care from the perspective of patients in eleven countries 
indicated that the United Kingdom’s National Health Service 
had many favorable attributes in coordination of care that pro-
mote efficiency.135 This typically included a higher probability 
of test results being available at the time of appointments or 
fewer duplicate tests ordered, higher probability of doctors 
being informed of their patients’ hospital and surgical care, 
and fewer gaps in the planning of discharge care following 
hospitalization in comparison to systems with fragmented 
or competing funding agents.135 These benefits may not be 
solely attributable to the structure of the health system, as 
staff training, health service culture, incumbent processes, 
and other factors are likely to have played a role, but it is 
likely that the structure of health systems will undoubtedly 
contribute (for better or worse) to the efficiency in resource 
usage and effectiveness of care provided for people with 
multimorbidity.
A particularly difficult and potentially contentious cir-
cumstance for consideration in any discussion of resource 
allocation decision making is that related to end-of-life 
care.136,137 There is clear evidence that people with many 
health conditions utilize substantially greater health care 
resources than those with fewer or no comorbid health condi-
tions during the last year of their life.54,138,139 A key point for 
consideration when it comes to practical policy and clinical 
practice considerations regarding end-of-life care is that 
it may be very difficult to determine when a person with 
multiple chronic conditions is about to experience negative 
health events that result in mortality. A person with multi-
morbidity may experience many nonterminal acute events 
or exacerbation of symptoms over the last decades of their 
life for which contemporary health care interventions would 
extend the quantity and quality of their life in a meaningful 
(and potentially cost-efficient) way. As a result, it is very 
difficult to make resource allocation decisions at a universal 
policy level when it comes to end-of-life care for people 
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with multimorbidity. Frost et al139 reported a systematic 
review that considered both patient and health care profes-
sional factors associated with decision making in end-of-life 
care. They concluded that patient age and comorbidities 
present were influential factors for both patients and health 
 professionals during health care decision making in times of 
critical illness.139 Further research and open discussion about 
end-of-life decision making among critically ill people with 
multimorbidity is warranted.
Priorities for research
Opportunities for research in the field of multimorbidity 
abound. However, this discussion will be limited to a few 
priorities for research regarding health care costs, cost-
effectiveness of interventions or models of care, and resource 
allocation decision making. While the identification of some 
research priorities is intended to stimulate further discussion 
or debate, this is by no means intended as an exhaustive list 
of research priorities in the field.
The impact of multimorbidity on health care costs and 
resources will likely differ greatly across health systems, geo-
graphical regions, disease combinations, and person-specific 
factors (including social disadvantage and age).1,9,37,46,53,63,69 
Most studies exploring the impact of multimorbidity on 
health care costs and resources to date have been generated 
from relatively few health systems and regions. Investigations 
to understand the impact of multimorbidity on health care uti-
lization in other health systems and regions would be useful 
for informing policy and practice in those (and similar) sys-
tems. Similarly, multimorbidity intervention studies to date 
have tended to focus on relatively few disease combinations, 
or chronic disease risk factors, with limited consideration 
of the potential impact of intervening in concordant versus 
discordant disease combinations.12,14,82,88,91,114,140,141
There is potential opportunity for further investiga-
tions to understand the cost effectiveness of implementing 
what has been termed “minimally disruptive medicine” 
approaches for people with multimorbidity at a health 
service level.142,143 Minimally disruptive medicine seeks 
to address a patient’s key health concerns with minimally 
disruptive interventions that are least likely to overwhelm 
patients who may have large burdens of disease. An under-
pinning principle is that a minimally disruptive intervention 
may have a higher chance of being adhered to, and therefore 
more effective than prescription of a broader range of inter-
ventions that have a lower chance of being adhered to due to 
a greater burden on the patient.142,143 Promoting minimally 
disruptive medicine may be a  cost-effective system-level 
approach to providing cost-effective care for patients with 
multimorbidity. This is in contrast to promoting many com-
plex, burdensome, and potentially expensive interventions 
that may deliver diminishing returns, particularly if they 
are not being adhered to by patients who have substantial 
cumulative complexity.
The cumulative complexity associated with multimor-
bidity has been conceptualized in terms of how clinical 
and social factors accumulate and interact to complicate 
patient care in through an imbalance between a patient’s 
“workload” and their “capacity” to manage that workload.143 
When the demand on a patient exceeds their capacity to 
manage, there may be a higher likelihood of nonadherence 
with  disease management recommendations contributing 
to greater morbidity or mortality. In this context, patient 
workload may include treatment, self-care demands, and 
other general life demands, while patient capacity refers to 
a patient’s ability to cope with these demands.143 A patient’s 
capacity may be impacted by their functional abilities, 
 financial resources, health literacy, and other factors. People 
with multimorbidity may be prone to unfavorable imbalances 
regarding their ability to meet the demands of managing their 
health conditions. However, at the present time, there is a 
scarcity of research investigating the cost-effectiveness of 
specific minimally disruptive medicine approaches among 
patients with multimorbidity and this remains a priority for 
further research.
It is likely that particular combinations of concordant 
diseases (and chronic disease risk factors) will offer greater 
opportunities for cost-effective interventions to improve 
health and reduce health care costs than others.141 This is 
particularly true if a single intervention may be able to have 
a positive impact on several of the diseases within a common 
disease cluster. For example, physical activity promoting 
interventions suitable for people with multimorbidity may 
be cost-effective for mitigating risks associated with the 
cluster of conditions represented in metabolic syndrome. 
Furthermore, investigations to understand the impact of 
multimorbidity on non-chronic disease-related health system 
interactions are also worthy of investigation. For example, a 
greater understanding of the impacts of multimorbidity on 
acute trauma management and rehabilitation may identify 
opportunities for enhancing the quality, safety, and efficiency 
of health care services for people with multimorbidity who 
have sustained trauma.
Economic evaluations, and cost-effectiveness studies in 
particular, investigating health care interventions and mod-
els of care among people with multimorbidity will provide 
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valuable information to inform resource allocation policy 
and clinical models of care. This includes interventions or 
models of care specifically targeted to patient populations 
with multiple chronic conditions, particularly those whereby 
the intervention can have a sustained impact on risk factors 
linked with future negative (and costly) health events. Cost-
effectiveness studies targeting combinations of conditions 
that have been reported to have the greatest burden (on 
health and health care costs for society) may have the great-
est scope for improving reducing costs where interventions 
demonstrate effectiveness among people with multimorbidity.
However, there is also a more general requirement to con-
sider the cost-effectiveness of single-disease interventions with 
data that is inclusive of patients with comorbidities that are most 
frequently observed alongside the target condition. Clinical trial 
samples representative of clinical practice populations are likely 
to enhance the robustness of economic evaluation findings for 
application in clinical practice settings.25,72,73 This is in contrast 
to economic evaluations derived from studies where complex 
patients with multimorbidity or advanced age are excluded by 
design or underrepresented due to pragmatic factors.
Finally, health services research that quantifies the effects 
of resource allocation decisions on the health of patients and 
health care costs at a systems level may be among the most 
important and influential research that can occur in the field 
of multimorbidity. Health care policy decisions are usually 
made under conditions of uncertainty, whether the level of 
uncertainty is known or not. However, robust evaluation 
of the implementation of new interventions or alternative 
models of care for people with multimorbidity will likely 
offer valuable insight into the cost-effectiveness of interven-
tions beyond that which can be derived from conventional 
 randomized  controlled trials. The field of implementa-
tion science has made very good advancements in recent 
decades and has great potential for further application in the 
 context of interventions and models of care for people with 
 multimorbidity and complex health care requirements.144,145
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